Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.

doi:10.1093/cid/cix916

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 19 Mar 2018

de Lédinghen Victor, Laforest Claire, Hézode Christophe, Pol Stanislas, Renault Alain, Alric Laurent, Larrey Dominique, Métivier Sophie, Tran Albert, Jézéquel Caroline, Samuel Didier, Zoulim Fabien, Tual Christelle, Pailhé Aurélie, Gibowski Séverine, Bourlière Marc, Bellissant Eric, Pawlotsky Jean-Michel

Abstract excerpt

Background: Failure to achieve sustained virological response (SVR) with hepatitis C virus (HCV) direct-acting antiviral (DAA)-based regimens is commonly associated with emergence of resistance-associated substitutions (RASs). Retreatment of patients who failed prior DAAs remains challenging. The aim of this prospective and randomized study was to evaluate the efficacy (primary endpoint: SVR 12 weeks after end of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzofurans

Share to Carbamates

Share to Cyclopropanes

Share to Quinoxalines

Share to Retreatment

Share to Sofosbuvir

Share to Sustained Virologic Response

Source

Open in PubMed

Identifiers

PMID: 29077864
DOI: 10.1093/cid/cix916

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.PMID 29077864Read ↗

Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection.Semantic proximity Read ↗

Emergence of HCV resistance-associated variants in patients failing sofosbuvir-based regimens: an observational cohort.Semantic proximity Read ↗

Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection.Semantic proximity Read ↗

Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.Semantic proximity Read ↗

Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.Semantic proximity Read ↗

Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting AntiviralsSemantic proximity Read ↗

Short article: Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience.Semantic proximity Read ↗

Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r.Semantic proximity Read ↗

Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

Retreatment of chronic hepatitis C virus genotype-4 patients after non-structural protein 5A inhibitors' failure: efficacy and safety of different regimens.Semantic proximity Read ↗

Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C.Semantic proximity Read ↗

Three regimens for re-treatment failure of Sofosbuvir-based therapy for chronic hepatitis-C genotype-4: a cohort study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.